94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Lisa Bartmann1,2
David Schumacher2Saskia von Stillfried3Marieke Sternkopf2Setareh Alampour-Rajabi2Marc A. M. J. van Zandvoort2,4
Fabian Kiessling1*†Zhuojun Wu1,2*†- 1Institute for Experimental Molecular Imaging, University Clinic, RWTH Aachen University, Aachen, Germany
- 2Institute for Molecular Cardiovascular Research, University Clinic, RWTH Aachen University, Aachen, Germany
- 3Institute of Pathology, University Clinic, RWTH Aachen University, Aachen, Germany
- 4Department of Genetics and Molecular Cell Biology, School for Cardiovascular Diseases (CARIM), School for Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, Netherlands
A corrigendum on
Evaluation of Riboflavin Transporters as Targets for Drug Delivery and Theranostics
by Bartmann, L., Schumacher, D., von Stillfried, S., Sternkopf, M., Alampour-Rajabi, S., van Zandvoort, M. A. M. J., Kiessling, F., and Wu, Z. Front. Pharmacol. 10:79. doi:10.3389/fphar.2019.00079
In the original article, there was an error. A statement on author contribution was incorrect. A correction has been made to the Author Contributions:
Author Contributions
ZW and FK contributed to conception, design of the study, and corrected the manuscript. LB collected the experimental data and wrote the manuscript. ZW, MvZ, LB, DS, SvS, MS, and SA-R contributed to data analysis and experimental execution. All authors contributed to manuscript revision, read and approved the submitted version.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: riboflavin, RFVT, theranostic, nanocarrier, cancer therapy, targeting molecules
Citation: Bartmann L, Schumacher D, von Stillfried S, Sternkopf M, Alampour-Rajabi S, van Zandvoort MAMJ, Kiessling F and Wu Z (2020) Corrigendum: Evaluation of Riboflavin Transporters as Targets for Drug Delivery and Theranostics. Front. Pharmacol. 11:617329. doi: 10.3389/fphar.2020.617329
Received: 14 October 2020; Accepted: 20 October 2020;
Published: 26 November 2020.
Edited and reviewed by:
Salvatore Salomone, University of Catania, ItalyCopyright © 2020 Bartmann, Schumacher, von Stillfried, Sternkopf, Alampour-Rajabi, van Zandvoort, Kiessling and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Fabian Kiessling, ZmtpZXNzbGluZ0B1a2FhY2hlbi5kZQ==; Zhuojun Wu, end1QHVrYWFjaGVuLmRl
†These authors have contributed equally to this work